cyclic heptapeptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-12-11. Anything still debated is marked as such rather than presented as settled.
Compared with the related compound melanotan II, PT-141 shows markedly weaker activation of receptors tied to pigmentation. This difference stems from subtle structural variations that alter affinity distribution across receptor subtypes. Investigators propose that such selectivity produces a different side effect profile in specific applications. However, downstream consequences of prolonged receptor activation remain uncertain in the literature. Published studies do not fully agree on the duration of signaling pathway activity and the mechanisms of desensitization.
From a pharmacokinetic standpoint, the peptide is usually delivered by injection because oral bioavailability is very low; proteases in the digestive tract degrade it rapidly. After subcutaneous administration, plasma concentrations reach a peak within roughly one hour. Its elimination half-life is relatively short, with most reports placing it in the range of a few hours. Nasal formulations have also been examined, though absorption varies widely between individuals. Metabolism proceeds mainly through peptidase cleavage, and the resulting products are excreted by the kidneys.
PT-141 initiates cellular signaling by binding to specific subtypes within the melanocortin receptor family. These receptors belong to the G protein-coupled receptor superfamily, and activation raises intracellular cyclic adenosine monophosphate levels. This cascade ultimately influences neuronal circuits in the central nervous system that are associated with sexual desire and arousal. Research indicates the compound's action concentrates in hypothalamic regions rather than peripheral tissues, which helps explain some observed pharmacological features. The selectivity of receptor binding underlies its functional differences.
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.
| Property | Value | Notes |
|---|---|---|
| Primary target | Melanocortin receptors | Mainly the MC4R subtype |
| Route of administration | Injection | Typically subcutaneous |
| Time to peak | About 60 minutes | After subcutaneous dosing |
| Elimination half-life | Roughly 2 to 3 hours | Values vary across reports |
| Metabolic pathway | Peptidase hydrolysis | Cleared by the kidneys |
Bremelanotide acts as an agonist at several melanocortin receptors, with the strongest reported activity at MC4R and measurable activity at MC1R and MC3R. Because MC4R is expressed in hypothalamic and limbic circuits, the proposed mechanism links receptor activation to modulation of central pathways involved in desire rather than to direct effects on peripheral genital tissue. The precise downstream steps remain incompletely characterized, and evidence for the involvement of specific neurotransmitters is suggestive rather than settled. Nausea and blood pressure elevation reported during trials are consistent with melanocortin signaling outside the intended target circuit.
Compared with melanotan II, bremelanotide is a smaller cyclic peptide with a more constrained backbone, which affects receptor selectivity and metabolic stability. Published descriptions give a plasma half-life on the order of a few hours after subcutaneous administration, with elimination through hepatic and renal routes and limited plasma protein binding. Central access is inferred from effects observed in animal models, although direct measurement in humans is limited. Handling and storage requirements follow from the peptide backbone, which is susceptible to hydrolysis and oxidation.
The melanocortin system comprises five G protein-coupled receptors, designated MC1 through MC5, that signal mainly through cyclic AMP accumulation. MC1R and MC2R are associated with pigmentation and adrenal steroid production, while MC3R and MC4R are expressed in the central nervous system and influence energy balance and behavior. MC5R appears in exocrine tissues. Natural agonists include alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone, and endogenous antagonists such as agouti-related protein modulate the same sites. This receptor family provides the framework within which bremelanotide activity is described.
Clinical development of bremelanotide proceeded through several reformulation attempts. An early intranasal version was discontinued, and a subcutaneous auto-injector formulation later received approval for hypoactive sexual desire disorder in premenopausal women. Approval decisions have varied by country and over time, and the product has not been universally adopted. Blood pressure elevation is a documented effect, which is why some jurisdictions require monitoring after administration. The clinical evidence base continues to evolve as additional studies are published.
Bremelanotide is a cyclic heptapeptide that acts as an agonist at melanocortin receptors. It binds MC1R, MC3R, MC4R, and MC5R, with MC4R activation considered most relevant to sexual desire pathways in the central nervous system. The molecule is a synthetic analog of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and energy regulation. Early research explored its use in tanning before attention shifted toward sexual dysfunction applications. Receptor binding affinity varies across these subtypes.
Activation of MC4R in the hypothalamus is thought to influence dopaminergic signaling, which in turn affects arousal and desire. This mechanism differs from that of phosphodiesterase type 5 inhibitors, which act primarily on vascular smooth muscle in the genital region. Because the pathway is central rather than peripheral, effects are not strictly dependent on local blood flow. The precise downstream cascade linking receptor binding to behavioral outcomes remains an area of ongoing investigation.
Across literature and commercial listings, the substance appears under several names, including bremelanotide, PT-141, and various brand designations. A CAS registry number provides a unique identifier for the compound, aiding retrieval from chemical databases. Synonym lists may also contain early development codes and descriptive chemical names. When consulting sources, researchers need to confirm that the cited names refer to the same molecular structure to avoid confusion. Naming consistency matters especially when comparing analytical data across publications.
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
Reported pharmacodynamic effects include transient rises in blood pressure and heart rate, flushing, nausea and headache, appearing soon after dosing and resolving within hours. These responses were dose-related in early studies and shaped the label's cardiovascular cautions and blood pressure monitoring advice. Gastrointestinal upset is the most frequent reason cited for discontinuation in trials. Whether the vascular signal attenuates with repeated use is not settled. Central effects on desire are described as emerging over weeks rather than immediately, which points to a cumulative rather than acute process.
The compound binds several melanocortin receptor subtypes rather than a single target, with the strongest functional activity reported at MC4R and measurable activity at MC1R, MC3R and MC5R. MC4R populations are dense in hypothalamic nuclei that integrate energy balance, autonomic tone and reproductive behaviour, which is the anatomical basis for the proposed pro-desire effect. Because binding is not subtype-selective, pigmentary and vascular effects accompany central activity. Improving subtype selectivity is an active area of analogue design. Direct causal mapping from receptor occupancy to reported desire change in humans is not fully established.
After subcutaneous dosing, peak plasma concentrations appear within roughly one hour, and elimination is fast, with a half-life on the order of a few hours. Degradation is mainly proteolytic, and at least one circulating fragment retains receptor activity, so parent-drug levels alone do not describe total exposure. Clearance does not depend heavily on hepatic cytochrome enzymes, which lowers the likelihood of common metabolic interaction routes. Data in renal or hepatic impairment are limited. Repeated dosing does not appear to produce marked accumulation given the short half-life.
==== Canaloplasty ==== Canaloplasty is a nonpenetrating procedure using microcatheter technology. To perform a canaloplasty, an incision is made into the eye to gain access to the Schlemm's canal, similarly to a viscocanalostomy. A microcatheter will circumnavigate the canal around the iris, enlarging the main drainage channel and its smaller collector channels through the injection of a sterile, gel-like material called viscoelastic. The catheter is then removed, and a suture is placed within the canal and tightened. By opening the canal, the pressure inside the eye may be relieved, although the reason is unclear, since the canal (of Schlemm) does not have any significant fluid resistance in glaucoma or healthy eyes. Long-term results are not available.
=== Vascular endothelium and microangiopathy === An upregulation of vascular cell adhesion molecule-1 is observed in NL tissue, indicating leukocyte aggregation and an inflammatory response. Furthermore, there is a reduced VEGF expression along with AGE-mediated cross-linking, reducing ECM fluidity. Both factors impair new vessel growth, lead to poor oxygenation, and impair tissue healing.
Such designers included Dave McDermott, who initially ran the Sven Co-op website before becoming a developer of it. Fearon had planned from the onset to include support for cooperatively playing through Half-Life's single-player campaign within Sven Co-op, but this was hampered initially by how the game's engine transitions from map to map, and made it difficult to keep players together in the multiplayer approach. Ultimately, the team was able to work this out, and later added support for Half-Life's two expansions, Half-Life: Opposing Force, and Half-Life: Blue Shift. Around 2004, prior to the release of Half-Life 2, Fearon had been planning to release Sven Co-op on Steam, but didn't due to confusion between the Sven Co-op team and Valve. Further, Fearon and the team had started work on a Sven Co-op 2 in anticipation of using the Source engine from Half-Life 2. Though they had developed a large number of assets for the mod, they were hindered by the lack of the SDK, which had been pushed back along with the release of Half-Life 2. Many of the team members had started to move on to other projects, and Fearon found they lost too many key members to continue development. Around this point Fearon opted to leave the project, giving the project lead over to Josh Polito. McDermott and Polito began negotiations with Valve to gain access to the GoldSrc engine around 2010 and to have Valve change some of the numerical limits originally imposed in the engine's use in Half-Life that would enable them to improve Sven Co-op.
Sources: en.wikipedia.org
== Chemistry == Chlorambucil is a white to pale beige crystalline or granular powder with a slight odor. When heated to decomposition it emits very toxic fumes of hydrogen chloride and nitrogen oxides
His discovery of sickle cell anemia as a "molecular disease" opened the way toward examining genetically acquired mutations at a molecular level. Pauling's 1951 publication with Robert B. Corey and H. R. Branson, "The Structure of Proteins: Two Hydrogen-Bonded Helical Configurations of the Polypeptide Chain," was a key early finding in the then newly emerging field of molecular biology. This publication was honored by a Citation for Chemical Breakthrough Award from the Division of History of Chemistry of the American Chemical Society presented to the department of chemistry, Caltech, in 2017.
7-Eleven, Inc. is an American convenience store chain headquartered in Irving, Texas. It is a wholly owned subsidiary of Seven-Eleven Japan, which is owned by Seven & I Holdings, a Japanese retail holding company. The chain was founded in 1927 as the Southland Ice Company, operating an ice house storefront in Dallas. Owned by the Southland Corporation, the chain expanded its convenience stores and renamed them Tote'm Stores between 1928 and 1946. The Southland Corporation changed the stores' name to 7-Eleven in 1946 to reflect their expanded hours of operation (7 a.m. to 11 p.m.). The Southland Corporation started franchising its stores in 1961. In 1973, Ito-Yokado, a Japanese supermarket chain, signed a franchise agreement with the Southland Corporation to develop 7-Eleven convenience stores in Japan. Later in 1991, operating the Japanese stores under Seven-Eleven Japan, Ito-Yokado acquired a 70% stake in the Southland Corporation. As the majority owner, it changed the Southland Corporation's name to 7-Eleven, Inc. Ito-Yokado expanded to 100% ownership in November 2005, making 7-Eleven, Inc. a wholly owned subsidiary of Seven-Eleven Japan. That same year, Ito-Yokado reorganized its collective businesses into the holding company Seven & I Holdings, with 7-Eleven, Inc. remaining wholly held by Seven-Eleven Japan. 7-Eleven operates, franchises, and licenses roughly 85,000 stores in 20 countries and territories as of August 2024. Its stores operate under its namesake brand globally.
=== Acting roles === Flay had a cameo appearance in the Disney Channel original movie Eddie's Million Dollar Cook-Off as the host of the cook-off. He appeared on the television game show Pyramid with fellow Iron Chef Mario Batali as the guest celebrities in an episode originally airing on November 18, 2003. He appeared as a judge on the CBS television show "Wickedly Perfect" during the 2004–05 season. He also appeared in the Law & Order: Special Victims Unit episode "Design", which originally aired on September 22, 2005. He had a small role as himself in the 2006 film East Broadway, in which his then-wife, Stephanie March, had a larger role. Jeopardy! featured a special "Throwdown with Bobby Flay" category during the March 12, 2008, episode, in which each of the clues featured Flay. He participated in the 2008 Taco Bell All-Star Legends and Celebrity Softball Game played at Yankee Stadium after the 2008 MLB All Star Game; Flay played for the National League. Flay is mentioned in the 2008 film Step Brothers in the "Derek comes for dinner" scene. In 2010, Flay was impersonated in the South Park cartoon episode "Crème Fraiche". In 2011, Flay had recurring appearances in the final season of Entourage as the boyfriend of Ari Gold's wife. In 2012, Flay appeared on Portlandia in a director's cut of the episode Brunch Village in which he showed director Jonathan Krisel how to make marionberry pancakes. Flay guest stars as himself on season two of the TV series Younger, which initially aired in 2016.
Sources: en.wikipedia.org
It primarily activates specific subtypes in the melanocortin receptor family. These receptors are G protein-coupled and mediate signaling mainly within the central nervous system.
It activates pigmentation-related receptors more weakly. This selectivity is thought to alter its side effect profile.
Injection is the most common route. Nasal administration has been studied as well, though absorption varies considerably.
The code designates bremelanotide, a cyclic heptapeptide melanocortin receptor agonist. It served as an internal research identifier before the compound entered formal clinical development. The code and the generic name refer to the same molecule.